Compare RYTM & CACC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RYTM | CACC |
|---|---|---|
| Founded | 2008 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.2B |
| IPO Year | 2017 | 1996 |
| Metric | RYTM | CACC |
|---|---|---|
| Price | $86.84 | $444.51 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 1 |
| Target Price | $129.93 | ★ $470.00 |
| AVG Volume (30 Days) | ★ 709.0K | 243.1K |
| Earning Date | 05-25-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 28.34 | ★ 83.00 |
| EPS | N/A | ★ 36.38 |
| Revenue | N/A | ★ $2,317,200,000.00 |
| Revenue This Year | $57.46 | $91.73 |
| Revenue Next Year | $85.60 | $3.58 |
| P/E Ratio | ★ N/A | $13.56 |
| Revenue Growth | N/A | ★ 7.16 |
| 52 Week Low | $45.91 | $401.90 |
| 52 Week High | $122.20 | $549.75 |
| Indicator | RYTM | CACC |
|---|---|---|
| Relative Strength Index (RSI) | 37.19 | 35.95 |
| Support Level | $85.59 | $406.44 |
| Resistance Level | $96.92 | $522.77 |
| Average True Range (ATR) | 5.11 | 21.66 |
| MACD | -0.45 | -3.63 |
| Stochastic Oscillator | 21.76 | 1.21 |
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
Credit Acceptance Corp is a consumer finance company that specializes in automobile loans. These loans are offered through a U.S. nationwide network of automobile dealers that benefit from sales of vehicles to consumers who could otherwise not obtain financing. The company also benefits from repeat and referral sales, and from sales to customers responding to advertisements for financing, but qualify for traditional financing. The company derives its revenue from finance charges, premiums earned on the reinsurance of vehicle service contracts, and other fees. Of these, financing charges, including servicing fees, are by far a source of revenue.